Because of the low sensitivity and specificity of CEA in malignant tumors such as breast cancer in the early diagnosis and other applications, CEA should be combined with other tumor markers in auxiliary diagnosis, evaluation of effectiveness, and prognosis of tumor12. This evidence concerns the gene CEACAM5 and breast cancer.